PATENT CLAIM ANALYSIS

Application Number: 16067229
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2019-01
Patent Classification: ["514", "248000"]

Abstract:
The present invention relates to a crystalline form of a BTK kinase inhibitor and the preparation method thereof. In particular, the present invention relates to a crystal form I of (R)-4-amino-1-(1-(but-2-ynoyl)pyrrolidin-3-yl)-3-(4-(2,6-difluorophenoxy)phenyl)-1H-pyrrolo[2,3-d]pyridazin-7(6H)-one (the compound of formula (I)) and the preparation method thereof. The crystal form I of the compound of formula (I) obtained by the present invention has a good crystalline stability and chemical stability, and the crystallization solvent used has a low toxicity and low residue, thus making it more suitable for use in clinical treatment.

Claim (Index 10):
A crystal form I (R)-4-amino-1-(1-(but-2-ynoyl)pyrrolidin-3-yl)-3-(4-(2,6-difluorophenoxy)phenyl)-1H-pyrrolo[2,3-d]pyridazin-7(6H)-one, wherein the crystal form I has a characteristic X-ray powder diffraction spectrum as shown in  FIG. 3 .

Metadata:
- Claim Count in Document: 13.0
- Percentile: 94.0
- Lexical Diversity: 1.92308
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15546405', '15952234', '15516529', '15559516', '14418484']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7834739726294235
- 35 USC 102 Novelty (BERT): 0.4945308864367582
- Combined Prediction Score: 0.754579664010157
- Mean Citation Score: 242.225378
- Max Citation Score: 250.81743
- Similarity Product: 202.0076440198696

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test